GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » United Therapeutics Corp (BSP:U2TH34) » Definitions » Cyclically Adjusted Revenue per Share

United Therapeutics (BSP:U2TH34) Cyclically Adjusted Revenue per Share : R$10.51 (As of Mar. 2024)


View and export this data going back to 2023. Start your Free Trial

What is United Therapeutics Cyclically Adjusted Revenue per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

United Therapeutics's adjusted revenue per share for the three months ended in Mar. 2024 was R$67.904. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is R$10.51 for the trailing ten years ended in Mar. 2024.

During the past 12 months, United Therapeutics's average Cyclically Adjusted Revenue Growth Rate was 9.20% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 11.40% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 11.40% per year. During the past 10 years, the average Cyclically Adjusted Revenue Growth Rate was 16.40% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of United Therapeutics was 35.70% per year. The lowest was 11.40% per year. And the median was 23.20% per year.

As of today (2024-05-26), United Therapeutics's current stock price is R$56.21. United Therapeutics's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 was R$10.51. United Therapeutics's Cyclically Adjusted PS Ratio of today is 5.35.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of United Therapeutics was 15.95. The lowest was 2.88. And the median was 6.14.


United Therapeutics Cyclically Adjusted Revenue per Share Historical Data

The historical data trend for United Therapeutics's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

United Therapeutics Cyclically Adjusted Revenue per Share Chart

United Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - 10.87

United Therapeutics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - 10.48 10.87 10.51

Competitive Comparison of United Therapeutics's Cyclically Adjusted Revenue per Share

For the Biotechnology subindustry, United Therapeutics's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


United Therapeutics's Cyclically Adjusted PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, United Therapeutics's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where United Therapeutics's Cyclically Adjusted PS Ratio falls into.



United Therapeutics Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, United Therapeutics's adjusted Revenue per Share data for the three months ended in Mar. 2024 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=67.904/131.7762*131.7762
=67.904

Current CPI (Mar. 2024) = 131.7762.

United Therapeutics Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201406 13.554 100.560 17.762
201409 16.309 100.428 21.400
201412 17.033 99.070 22.656
201503 22.030 99.621 29.141
201506 20.817 100.684 27.246
201509 30.028 100.392 39.415
201512 31.616 99.792 41.749
201603 28.020 100.470 36.751
201606 30.117 101.688 39.028
201609 28.744 101.861 37.186
201612 30.282 101.863 39.175
201703 25.245 102.862 32.341
201706 32.631 103.349 41.606
201709 31.645 104.136 40.044
201712 34.800 104.011 44.090
201803 29.070 105.290 36.383
201806 38.622 106.317 47.871
201809 38.538 106.507 47.681
201812 33.662 105.998 41.848
201903 31.868 107.251 39.155
201906 32.738 108.070 39.920
201909 37.590 108.329 45.726
201912 29.153 108.420 35.433
202003 39.477 108.902 47.769
202006 42.302 108.767 51.251
202009 46.021 109.815 55.224
202012 43.810 109.897 52.532
202103 46.040 111.754 54.288
202106 47.468 114.631 54.568
202109 49.319 115.734 56.155
202112 49.017 117.630 54.912
202203 48.189 121.301 52.350
202206 48.997 125.017 51.646
202209 55.558 125.227 58.464
202212 52.189 125.222 54.921
202303 53.231 127.348 55.082
202306 58.490 128.729 59.875
202309 60.556 129.860 61.450
202312 60.238 129.419 61.335
202403 67.904 131.776 67.904

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.


United Therapeutics  (BSP:U2TH34) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

United Therapeutics's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=56.21/10.51
=5.35

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of United Therapeutics was 15.95. The lowest was 2.88. And the median was 6.14.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


United Therapeutics Cyclically Adjusted Revenue per Share Related Terms

Thank you for viewing the detailed overview of United Therapeutics's Cyclically Adjusted Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


United Therapeutics (BSP:U2TH34) Business Description

Industry
Traded in Other Exchanges
Address
1040 Spring Street, Silver Spring, MD, USA, 20910
United Therapeutics specializes in drug development for pulmonary arterial hypertension, a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. Most of the company's sales are generated within the United States. United Therapeutics also markets a pediatric oncology drug, but its focus largely remains in pulmonary arterial hypertension.

United Therapeutics (BSP:U2TH34) Headlines

No Headlines